Literature DB >> 14693407

Daily nasal inoculation with the insulin gene ameliorates diabetes in mice.

S-i Tanaka1, T Yamakawa, M Kimura, I Aoki, J Kamei, K Okuda, C Mobbs.   

Abstract

The present study examined the feasibility of liposome-mediated gene transfer via nasal administration, for treating insulin-dependent diabetes mellitus. The rat insulin gene was packed under control of the CMV promoter, complexed with DC-chol/DOPE-based liposomes and administered daily via the nasal route in mice made severely diabetic by streptozocin. Sustained expression of the insulin gene was achieved and insulinopenia, ketonuria and death were prevented. Hyperglycemia and body weight reduction were significantly suppressed without evidence of hypoglycemia throughout the experimental period. RT-PCR and FISH analysis indicated that insulin was produced in the alveolar epithelial cells of the lung. Liposome-mediated in vivo gene transfer via nasal administration may provide an efficacious route for delivery of hormonal and other gene products into the blood stream.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693407     DOI: 10.1016/j.diabres.2003.07.005

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  3 in total

1.  Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy.

Authors:  In-Kwon Han; Mi Young Kim; Hyang-Min Byun; Tae Sun Hwang; Jung Mogg Kim; Kwang Woo Hwang; Tae Gwan Park; Woon-Won Jung; Taehoon Chun; Gil-Jae Jeong; Yu-Kyoung Oh
Journal:  J Mol Med (Berl)       Date:  2006-11-07       Impact factor: 4.599

Review 2.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

Review 3.  Barriers to Liposomal Gene Delivery: from Application Site to the Target.

Authors:  Mostafa Saffari; Hamid Reza Moghimi; Crispin R Dass
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.